PREVENZIONE DELLE INFEZIONI NEL CIRROTICO. UNA GRANDE REVIEW OPEN. DA “Semin Liver Dis” (FREE !). GUARDATE PER CREDERE!

CIRROSI EPATICA, EPATOLOGIA, GASTROENTEROLOGIA, MEDICI DI FAMIGLIA, MEDICINA INTERNA, Senza categoriaLascia un commento

Early Diagnosis and Prevention of Infections in Cirrhosis Anand V. Kulkarn et al. Abstract Strategies to prevent infection and improve outcomes in patients with cirrhosis. HAV, hepatitis A virus; HBV, hepatitis B virus; COVID-19, novel coronavirus disease 2019; NSBB, nonselective β-blocker; PPI, proton pump inhibitors. Cirrhosis is a risk factor for infections. Majority of hospital…

TRIAL OGGI ? USATA LA LIKELIHOOD RATIO INVECE DEL RISCHIO RELATIVO! INTERESSANTE … DA “BMJ Evidence-Based Medicine”.

METODOLOGIA, REAL WORLD EVIDENCE, Senza categoriaLascia un commento

Likelihood ratio interpretation of the relative risk Suhail A R Doi et al. Interpreting diagnostic test results in medicine The likelihood ratio (LR) is today commonly used in medicine for diagnostic inference. Historically, it was preceded by introduction, in 1966, of the predictive value of a diagnostic test in Medicine1 and within a decade of the…

RIFAXIMINA E SIMVASTATINA MIGLIORANO IL PROFILO PLASMATICO DEI METABOLITI IN CORSO DI CIRROSI SCOMPENSATA. DA “Hepatology Communications” (FREE).

CIRROSI EPATICA, EPATOLOGIA, GASTROENTEROLOGIA, MEDICINA INTERNA, Senza categoriaLascia un commento

Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis Elisa Pose, et al. Abstract Patients with decompensated cirrhosis, particularly those with acute‐on‐chronic liver failure (ACLF), show profound alterations in plasma metabolomics. The aim of this study was to investigate the effect of treatment with simvastatin and rifaximin on plasma…

RIFAXIMINA + LUBIPROSTONE: RIDUZIONE DELLA FIBROSI VIA RIPARAZIONE DELLA BARRIERA MUCOSA. UN MODELLO ANIMALE DA SEGUIRE

CIRROSI EPATICA, EPATOLOGIA, GASTROENTEROLOGIA, MICROBIOTA, Senza categoriaLascia un commento

Rifaximin and lubiprostone mitigate liver fibrosis development by repairing gut barrier function in diet–induced rat steatohepatitis Masahide Enomoto et al. Abstract Background Although gut-derived lipopolysaccharide (LPS) affects the progression of non-alcoholic steatohepatitis (NASH) pathogenesis, few studies have focused on this relationship to develop treatments for NASH. Aims To explore the effects of combination with rifaximin…

STANDARD CONSIGLIATO PER I TRIAL SUL CANCRO DEL PANCREAS , RESECABILE, O BORDERLINE RESECABILE. UN IMPORTANTE CONSENSUS STATEMENT DA “JAMA SURGERY” .

CHIRURGIA, GASTROENTEROLOGIA, METODOLOGIA, PANCREAS E VIE BILIARI, Senza categoriaLascia un commento

Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB). A Systematic Review and Delphi Consensus Statement. Esther N. Pijnappel et al. Abstract Importance  Pancreatic cancer is the third most common cause of cancer death; however, randomized clinical trials (RCTs) of survival in patients with resectable pancreatic cancer…

ULTIMA META-ANALISI SU RIFAXIMINA ED ENCEFALOPATIA EPATICA . ABSTRACT DAL “J. OF HEPATOLOGY”. NNT = 5; participants = 969 PER OUTCOME REGRESSIONE ENCEFALOPATIA

CIRROSI EPATICA, ENCEFALOPATIA, EPATOLOGIA, GASTROENTEROLOGIA, MEDICINA INTERNA, Senza categoriaLascia un commento

Rifaximin for the prevention and treatment of hepatic encephalopathy: a systematic review and meta-analysis of randomized clinical trials Harry Demetrios Zacharias et al. SAT501 Rifaximin for the prevention and treatment of hepatic encephalopathy: a systematic review and meta-analysis of randomized clinical trials Harry D Zacharias1, Jaclyn Yizhen Tan1, Fady Kamel1, Nina Kimer2, Lise Lotte Gluud2,…